title: [CYLD deubiquitinase as a recurrent target in oncogenic processes].
abstract: CYLD deubiquitinase has been originally defined as a tumor suppressor based exclusively on genetic findings. Indeed, inactivation of CYLD in humans results in familial cylindromatosis and multiple trichoepithelioma, two pathologies characterized by the development of tumors originating specifically from the skin appendages. A set of recent publications has revealed that recurrent inactivation of CYLD occurs through diverse mechanisms in several forms of cancer, unequivocally confirming its tumor suppressor function. This property is associated with the critical role played by CYLD in negatively regulating several signaling pathway, among them the NF-κB signaling pathway.
authors: Institute of Genetics, University of Cologne, Cologne, Allemagne.
authors: Marion
authors: M
authors: Bonnet
authors: Gilles
authors: G
authors: Courtois
mesh_terms: D002471:Cell Transformation, Neoplastic / Q000235:genetics; D000074749:Deubiquitinating Enzyme CYLD; D005786:Gene Expression Regulation / Q000502:physiology; D016147:Genes, Tumor Suppressor; D006801:Humans; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D009386:Neoplastic Syndromes, Hereditary / Q000201:enzymology / Q000235:genetics; D011499:Protein Processing, Post-Translational / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology*; D012878:Skin Neoplasms / Q000201:enzymology / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D054875:Ubiquitination / Q000502:physiology
chemical_list: D016328:NF-kappa B; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD